Background/Purpose: Rheumatoid arthritis (RA) is a chronic, systemic inflammatory disorder that causes joint pain and swelling, bone erosions, and deformity. This debilitating disease can severely impact patients’ quality of life, employment opportunities, daily activities, and life expectancy. Over time, RA can cause the joints to become permanently deformed, which may lead to disability. Because of advances in treatment options such as biologic disease-modifying antirheumatic drugs (bDMARDs), many patients with RA are now able to continue to work and lead full lives, whereas decades ago this was not possible. The goal of this study was to assess the impact of introducing bDMARDs as a treatment option for patients with RA.
Conclusion: The simulation model estimates show that biologics will reduce the RA population disability burden and increase the life span of RA patients. The model can be used to estimate additional population outcomes including costs and healthcare resource use.
2018 ACR/ARHP Annual Meeting Abstract Supplement
Mauskopf, J., Gharaibeh, M., Wamble, D., Collier, D., Stolshek, B. S., & Matteson, E. L. (2018). 2018 ACR/ARHP Annual Meeting Abstract Supplement. Arthritis and Rheumatology, 70(S9), 1-3553. [1533]. https://doi.org/10.1002/art.40700
Abstract
Publications Info
To contact an RTI author, request a report, or for additional information about publications by our experts, send us your request.
Meet the Experts
View All ExpertsRecent Publications
Article
The daily association between affect and alcohol use: A meta-analysis of individual participant data
Article
Protection of forest ecosystems in the eastern United States from elevated atmospheric deposition of sulfur and nitrogen
Article
The use of patient experience feedback in rehabilitation quality improvement and codesign activities
Article